Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo

Cancer Letters

Volumn 287, Issue 2, 2010, Pages 196-206

  Cho, Seung Ju ^a   Lee, Seung Soo ^a   Kim, Young Jong ^b   Park, Byoung Duck ^a   Choi, Joon Seok ^a   Liu, LinHua ^a   Ham, Young Mi ^a   Moon Kim, B ^b   Lee, Seung Ki ^a  

^a Research Institute of Pharmaceutical Sciences   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Apoptosis; Cyclin dependent kinase; Hepatocellular carcinoma (HCC); Xenograft; Xylocydine

Indexed keywords

CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RNA POLYMERASE II; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; XYLOCYDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; UPREGULATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, HEPATOCELLULAR; CDC2 PROTEIN KINASE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 9; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEP G2 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NUCLEOSIDES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA POLYMERASE II; TIME FACTORS; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 72949096990     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.06.011     Document Type: Article

References (48)

1. Bosch F.X., Ribes J., Diaz M., and Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127 (2004) S5-S16
2. Hu J., and Ludgate L. HIV-HBV and HIV-HCV coinfection and liver cancer development. Cancer Treat. Res. 133 (2007) 241-252
3. Burroughs A., Hochhauser D., and Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol. 5 (2004) 409-418
4. Huang C.C., Wu M.C., Xu G.W., Li D.Z., Cheng H., Tu Z.X., Jiang H.Q., and Gu J.R. Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J. Natl. Cancer Inst. 84 (1992) 262-264
5. Senderowicz A.M. Small-molecule cyclin-dependent kinase modulators. Oncogene 22 (2003) 6609-6620
6. Swanton C. Cell-cycle targeted therapies. Lancet Oncol. 5 (2004) 27-36
7. Senderowicz A.M. Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr. Opin. Cell Biol. 16 (2004) 670-678
8. Ito Y., Takeda T., Sakon M., Monden M., Tsujimoto M., and Matsuura N. Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma. Oncology 59 (2000) 68-74
9. McClue S.J., Blake D., Clarke R., Cowan A., Cummings L., Fischer P.M., MacKenzie M., Melville J., Stewart K., Wang S., Zhelev N., Zheleva D., and Lane D.P. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 102 (2002) 463-468
10. Fischer P.M., and Gianella-Borradori A. CDK inhibitors in clinical development for the treatment of cancer. Expert. Opin. Invest. Drugs 12 (2003) 955-970
11. Senderowicz A.M. Novel small molecule cyclindependent kinases modulators in human clinical trials. Cancer Biol. Ther. 2 (2003) S84-S95
12. De la Motte S., and Gianella-Borradori A. Pharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects. Int. J. Clin. Pharmacol. Ther. 42 (2004) 232-239
13. Ambrosini G., Seelman S.L., Qin L.X., and Schwartz G.K. The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. Cancer Res. 68 (2008) 2312-2320
14. Malumbres M., Pevarello P., Barbacid M., and Bischoff J.R. CDK inhibitors in cancer therapy: what is next?. Trends Pharmacol. Sci. 29 (2008) 16-21
15. Maddika S., Ande S.R., Panigrahi S., Paranjothy T., Weglarczyk K., Zuse A., Eshraghi M., Manda K.D., Wiechec E., and Los M. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist. Updat. 10 (2007) 13-29
16. Chao Y., Shih Y.L., Chiu J.H., Chau G.Y., Lui W.Y., Yang W.K., Lee S.D., and Huang T.S. Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma. Cancer Res. 58 (1998) 985-990
17. Ohashi R., Gao C., Miyazaki M., Hamazaki K., Tsuji T., Inoue Y., Uemura T., Hirai R., Shimizu N., and Namba M. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res. 21 (2001) 657-662
18. Yankulov K.Y., and Bentley D.L. Regulation of CDK7 substrate specificity by MAT1 and TFIIH. Embo J. 16 (1997) 1638-1646
19. Chao S.H., Fujinaga K., Marion J.E., Taube R., Sausville E.A., Senderowicz A.M., Peterlin B.M., and Price D.H. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 275 (2000) 28345-28348
20. Peterlin B.M., and Price D.H. Controlling the elongation phase of transcription with P-TEFb. Mol. Cell. 23 (2006) 297-305
21. Bao J.J., Zhang W.W., and Kuo M.T. Adenoviral delivery of recombinant DNA into transgenic mice bearing hepatocellular carcinomas. Hum. Gene Ther. 7 (1996) 355-365
22. Beliveau A., and Yaswen P. Soothing the watchman: telomerase reduces the p53-dependent cellular stress response. Cell Cycle 6 (2007) 1284-1287
23. Sakaguchi K., Sakamoto H., Lewis M.S., Anderson C.W., Erickson J.W., Appella E., and Xie D. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry 36 (1997) 10117-10124
24. Pospísilová S., Brázda V., Kucharíková K., Luciani M.G., Hupp T.R., Skládal P., Palecek E., and Vojtesek B. Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2. Biochem. J. 378 (2004) 939-947
25. Hao M., Lowy A.M., Kapoor M., Deffie A., Liu G., and Lozano G. Mutation of phosphoserine 389 affects p53 function in vivo. J. Biol. Chem. 271 (1996) 29380-29385
26. Wang Y., and Prives C. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 376 (1995) 88-91
27. Saito S., Yamaguchi H., Higashimoto Y., Chao C., Xu Y., Fornace Jr. A.J., Appella E., and Anderson C.W. Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J. Biol. Chem. 278 (2003) 37536-37544
28. Ham Y.M., Choi K.J., Song S.Y., Jin Y.H., Chun M.W., and Lee S.K. Xylocydine, a novel inhibitor of cyclin-dependent kinases, prevents the tumor necrosis factor-related apoptosis-inducing ligand-induced apoptotic cell death of SK-HEP-1 cells. J. Pharmacol. Exp. Ther. 308 (2004) 814-819
29. Knudsen E.S., and Wang J.Y. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J. Biol. Chem. 271 (1996) 8313-8320
30. Zarkowska T., and Mittnacht S. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J. Biol. Chem. 272 (1997) 12738-12746
31. MacCallum D.E., Melville J., Frame S., Watt K., Anderson S., Gianella-Borradori A., Lane D.P., and Green S.R. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 65 (2005) 5399-5407
32. Oelgeschlager T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J. Cell. Physiol. 190 (2002) 160-169
33. Lam L.T., Pickeral O.K., Peng A.C., Rosenwald A., Hurt E.M., Giltnane J.M., Averett L.M., Zhao H., Davis R.E., Sathyamoorthy M., Wahl L.M., Harris E.D., Mikovits J.A., Monks A.P., Hollingshead M.G., Sausville E.A., and Staudt L.M. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol. 2 (2001) RESEARCH0041
34. R. Chen, W.G. Wierda, S. Chubb, R.E. Hawtin, J.A. Fox, M.J. Keating, V. Gandhi, W. Plunkett, Mechanism of Action of SNS-032, a Novel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia, Blood (Epub ahead of print).
35. Hahntow I.N., Schneller F., Oelsner M., Weick K., Ringshausen I., Fend F., Peschel C., and Decker T. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 18 (2004) 747-755
36. Virrey J.J., Guan S., Li W., Schönthal A.H., Chen T.C., and Hofman F.M. Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. Am. J. Pathol. 173 (2008) 575-585
37. Tommasi S., Pinto R., Pilato B., and Paradiso A. Molecular pathways and related target therapies in liver carcinoma. Curr. Pharm. Des. 13 (2007) 3279-3287
38. Calvisi D.F., Pascale R.M., and Feo F. Dissection of signal transduction pathways as a tool for the development of targeted therapies of hepatocellular carcinoma. Rev. Recent Clin. Trials 2 (2007) 217-236
39. Bode A.M., and Dong Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4 (2004) 793-805
40. Appella E. Modulation of p53 function in cellular regulation. Eur. J. Biochem. 268 (2001) 2763
41. Appella E., and Anderson C.W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268 (2001) 2764-2772
42. Waterman M.J., Stavridi E.S., Waterman J.L., and Halazonetis T.D. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat. Genet. 19 (1998) 175-178
43. Banin S., Moyal L., Shieh S., Taya Y., Anderson C.W., Chessa L., Smorodinsky N.L., Prives C., Reiss Y., Shiloh Y., and Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281 (1998) 1674-1677
44. Keller D., Zeng X., Li X., Kapoor M., Iordanov M.S., Taya Y., Lozano G., Magun B., and Lu H. The p38MAPK inhibitor SB203580 alleviates ultraviolet-induced phosphorylation at serine 389 but not serine 15 and activation of p53. Biochem. Biophys. Res. Commun. 261 (1999) 464-471
45. Kapoor M., Hamm R., Yan W., Taya Y., and Lozano G. Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. Oncogene 19 (2000) 358-364
46. Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H., Goodman R., Lozano G., Zhao Y., and Lu H. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol. Cell 7 (2001) 283-292
47. Lu H., Taya Y., Ikeda M., and Levine A.J. Ultraviolet radiation, but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein at serine-389. Proc. Natl. Acad. Sci. USA 95 (1998) 6399-6402
48. Olsson A., Manzl C., Strasser A., and Villunger A. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression?. Cell Death Differ. 14 (2007) 1561-1575